+ Watch HZNP
on My Watchlist
With the addition of Videra & moving to Ireland, it is inexpensive relative to other specialty pharma
Great value play
doesn't look like Horizon Pharma Inc. is going to book any profits anytime soon.
This red thumb actually shouldn't be here. I reflexively red thumbed Horizon when I saw the share price spiking up over my threshold of 2.5, then canceled when I saw the surprisingly high quarterly Duexis revenues. At least I thought I did. At the end of the day I saw my underperform had actually gone through. It should be interesting to see what develops from here. I'm very suspicious of the recent numbers, given that the company has only recently terminated their co-promotion agreement with Mallinckrodt. I suspect this substantial uptick in revenues from this superfluous medication will not be sustained in coming quarters.
THEY ARE CREATING NEW HEALTH TECHNOLOGIES TO MAKE HEALTHCARE AND HEALTH SENSORS MORE ACCESSIBLE TO THE MASSES.
1) Insiders are in over $9. 2) Their drug is marketed overseas.3) # of shares outstanding is relatively small. 4) recently went public. 5) PDUFA
PDUFA coming up
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions